Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy

56Citations
Citations of this article
80Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

MicroRNAs (miRNAs), which are endogenous about 20-23 nucleotides non-coding RNAs, have been acted as post-transcriptional regulators of gene expression. Current studies demonstrated that miRNAs are promising candidates for tumor gene therapy because of their important biological functions in tumor cell proliferation, metastasis, apoptosis, and drug resistance. As an important delivery system, nanostructured lipid carriers (NLCs) have great potential in tumor gene therapy, particularly for miRNA delivery, due to low toxicity, low immunogenicity, long metabolic cycles, and easy modification. This article reviews recent research progress on NLCs for miRNA delivery in tumor gene therapy and prospective applications.

Cite

CITATION STYLE

APA

Wang, H., Liu, S., Jia, L., Chu, F., Zhou, Y., He, Z., … Xu, L. (2018, July 13). Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy. Cancer Cell International. BioMed Central Ltd. https://doi.org/10.1186/s12935-018-0596-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free